Andres Martin Acosta

Dr. Andres Martin Acosta

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SKSheng-Yu Ku
Sheng-Yu Ku
YWYanqing Wang
Yanqing Wang
MGMaria Mica Garcia
Maria Mica Garcia
YYYasutaka Yamada
Yasutaka Yamada
KMKei Mizuno
Kei Mizuno
HBHimisha Beltran
Himisha Beltran
Notch signaling can have either an oncogenic or tumor-suppressive function in cancer depending on the cancer type and cellular context. While Notch can be oncogenic in early prostate cancer, we identified significant downregulation of the Notch pathway during prostate cancer progression from adenocarcinoma to neuroendocrine (NE) prostate cancer, where it functions as a tumor suppressor. Activation of Notch in NE and Rb1 / Trp53 -deficient prostate cancer models led to phenotypic conversion toward a more indolent, non-NE state with glandular features and expression of luminal lineage markers. This was accompanied by upregulation of MHC and type I IFN and immune cell infiltration. Overall, these data support Notch signaling as a suppressor of NE differentiation in advanced prostate cancer and provide insights into how Notch signaling influences lineage plasticity and the tumor microenvironment (TME).

1 October 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
NRNatalie M. Rizzo
Natalie M. Rizzo
LSLynette Sholl
Lynette Sholl
MIMuhammad T. Idrees
Muhammad T. Idrees
JCJohn Cheville
John Cheville
SGSounak Gupta
Sounak Gupta
AAAndres Martin Acosta
Andres Martin Acosta

1 October 2016 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
AAAndres Martin Acosta
Andres Martin Acosta
EWElizabeth Louise Wiley
Elizabeth Louise Wiley
Mixed adenoneuroendocrine carcinomas (MANECs) are composite neoplasms with areas of adenocarcinoma or squamous cell carcinoma intermingled with neuroendocrine carcinoma or neuroendocrine tumor, each composing at least 30% of the neoplasm. MANECs are very infrequent overall, and they are more commonly diagnosed in the appendix, colon, and stomach. Biliary MANECs are particularly rare, and their histogenesis is debated because neuroendocrine cells are seldom identified in the normal biliary tract. They can show one of the 3 different architectural patterns described in Lewin's original classification: collision tumors, combined lesions, or amphicrine neoplasms. The neuroendocrine component is usually of a high grade, with small or large cell cytomorphology, whereas the adenocarcinoma component is either an intestinal or biliary type. Clinical presentation is characterized by locally advanced disease at the time of initial diagnosis. Recent studies suggest that treatment should be guided by the most aggressive histologic component.

27 August 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
NWNicolas Wyvekens
Nicolas Wyvekens
LSLynette Sholl
Lynette Sholl
YYYiying Yang
Yiying Yang
ITIvy Tran
Ivy Tran
VVVarshini Vasudevaraja
Varshini Vasudevaraja
AAAndres Martin Acosta
Andres Martin Acosta

19 June 2020 in Histopathology
Verified
Journal Article
Closed access
PDF file
AAAndres Martin Acosta
Andres Martin Acosta
LSLynette M. Sholl
Lynette M. Sholl
PCPaola Dal Cin
Paola Dal Cin
BHBrooke E Howitt
Brooke E Howitt
COChristopher N. Otis
Christopher N. Otis
MNMarisa R. Nucci
Marisa R. Nucci

1 March 2017 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
SDShweta Dambal
Shweta Dambal
AGAngeline A. Giangreco
Angeline A. Giangreco
AAAndres Martin Acosta
Andres Martin Acosta
AFAndrew Fairchild
Andrew Fairchild
ZRZachary Richards
Zachary Richards
LNLarisa Nonn
Larisa Nonn